Abstracts – 2008 - Obstetricia Crítica

J Perinatol. 2008 Feb 21 [Epub ahead of print]Urinalysis vs urine protein-creatinine ratio to predict significant proteinuriain pregnancy.Dwyer BK, Gorman M, Carroll IR, Druzin M.1Division of Maternal Fetal Medicine, Department of Gynecology and Obstetrics,Stanford University, Stanford, CA, USA.Objective: To compare the urine protein-creatinine ratio with urinalysis to predictsignificant proteinuria (>/=300 mg per day).Study Design: A total of 116 pairedspot urine samples and 24-h urine collections were obtained prospectively fromwomen at risk for preeclampsia. Urine protein-creatinine ratio and urinalysis werecompared to the 24-h urine collection.Result: The urine protein-creatinine ratiohad better discriminatory power than urinalysis: the receiver operatingcharacteristic curve had a greater area under the curve, 0.89 (95% confidenceinterval (CI) 0.83 to 0.95) vs 0.71 (95% CI 0.64 to 0.77, P/=0.28) ismore sensitive than urinalysis (cutoff >/=1+): 66 vs 41%, P=0.001 (with 95 and100% specificity, respectively). Furthermore, the urine protein-creatinine ratiopredicted the absence or presence of proteinuria in 64% of patients; urinalysispredicted this in only 19%.Conclusion: The urine protein-creatinine ratio is abetter screening test. It provides early information for more patients.Journal ofPerinatology advance online publication, 21 February 2008;doi:10.1038/jp.2008.4.J Perinatol. 2008 Feb 21 [Epub ahead of print]Patterns of pregnancy exposure to prescription FDA C, D and X drugs in aCanadian population.Wen SW, Yang T, Krewski D, Yang Q, Nimrod C, Garner P, Fraser W,Olatunbosun O, Walker MC.[1] 1OMNI Research Group, Department of Obstetrics and Gynecology,University of Ottawa, Ottawa, ON, Canada [2] 2Clinical Epidemiology Program,Ottawa Health Research Institute, Ottawa, ON, Canada [3] 3Department ofEpidemiology and Community Medicine, University of Ottawa, Ottawa, ON,Canada [4] 4School of Public Health, Central South University, Changsha,Hunan, China [5] 5McLaughlin Centre for Population Health Risk Assessment,Institute of Population Health, University of Ottawa, Ottawa, ON, Canada.Objective:To examine prescription Food and Drug Administration (FDA) C, D andX drugs in general obstetric population.Study Design:Historical cohortstudy.Result:A total of 18 575 women who gave a birth in Saskatchewanbetween January 1997 and December 2000 were included. Among them, 3604(19.4%) received FDA C, D or X drugs at least once during pregnancy. Thepregnancy exposure rates were 15.8, 5.2 and 3.9%, respectively, for category C,D and X drugs, and were 11.2, 7.3 and 8.2%, respectively, in the first, secondand third trimesters. Salbutamol (albuterol), trimethoprim/sulfamethoxazole (cotrimoxazole),ibuprofen, naproxen and oral contraceptives were the mostcommon C, D, X drugs used during pregnancy.Conclusion:About one in every